Scarica l'app Stockscreener
1.46
3.55%
0.05
Pre-mercato:
1.52
0.06
+4.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
BlackRock (CHRS holder) discloses 8.93M Coherus Oncology shares under sole control - Stock Titan
CHRS|Coherus BioSciences Inc|Price:1.465|Chg%:+0.055 - TradingKey
Coherus Oncology Market Sentiment - Benzinga España
CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.020 - TradingKey
Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook - Ad-hoc-news.de
Coherus Oncology to report Q2 2026 financial results on August 5 - scanx.trade
Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues - Ad-hoc-news.de
Coherus Oncology Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Coherus to webcast second-quarter results Aug. 5 at 5 p.m. - Stock Titan
Q3 2025 Coherus Oncology Inc Earnings Call Transcript - GuruFocus
Coherus Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Lanfear Dennis M - Moomoo
Coherus BioSciences stock stays supported by oncology focus - AD HOC NEWS
Coherus Oncology (CHRS) The Citizens JMP Life Sciences Conference 2025 Summary - Quartr
Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing - Ad-hoc-news.de
Coherus Oncology (CHRS) Hovers Near Support Levels After Slight DeclineFactor Crowding - dars.gov.et
CHRSCoherus Oncology Inc Options - Finviz
Coherus Oncology, Inc. Financial Disclosures & Filings - TradingView
Free cash flow per share of Coherus Oncology, Inc. – SWB:8C5 - TradingView
CHRS Q1 2026 Earnings: Strong EPS Beat Highlights Operational ProgressEarnings Quality Analysis - dars.gov.et
CHRS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock GainOperating Income Trends - dars.gov.et
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
CHRS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – LS:A12ETZ - TradingView
CHRS Should I Buy - Intellectia AI
Coherus Oncology, Inc. Actuals & Estimates (NASDAQ:CHRS) - TradingView
8C5 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Price to sales forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Coherus Oncology (CHRS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Coherus Oncology (CHRS) Proxy filing Summary - Quartr
Coherus Oncology (CHRS) Enters Clinical Collaboration for Phase 1 Trial - GuruFocus
Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics - marketscreener.com
Coherus and Zumutor announce phase 1 cancer trial collaboration - Investing.com
Coherus and Zumutor announce phase 1 cancer trial collaboration By Investing.com - Investing.com India
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Oncology and Zumutor Biologics Announce Phase 1 Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI - Quiver Quantitative
Coherus and Zumutor Biologics Announce Clinical - GlobeNewswire
Coherus doses first patient in cancer combo trial with Zumutor - Stock Titan
CHRS Q1 2026 Earnings: Narrower Loss Surprises as Coherus Advances PipelineRevenue Inflection Point - dars.gov.et
COHERUS ONCOLOGY INC (CHRS) Stock Chart - ChartMill
Coherus Oncology, Inc. 8-K SEC Filing June 12, 2026 – Entity Information, Common Stock, NASDAQ, and Exhibit Letter from Ernst & Young LLP 18205556 – Minichart - Minichart
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young - Investing.com Australia
[8-K] Coherus Oncology, Inc. Reports Material Event - Stock Titan
Coherus Oncology (CHRS) Slides 1.41% as Stock Tests Key Support at $1.33Momentum Stock Picks - dars.gov.et
Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant - Stock Titan
[Form 4] Coherus Oncology, Inc. Insider Trading Activity - Stock Titan
Coherus Oncology | 4: Statement of changes in beneficial ownership of securities-Director Wahlstrom Mats - Moomoo
CHRS: Immuno-oncology pipeline advances with key data and global deals expected in 6–18 months - TradingView
CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill
CHRS Q1 2026 Earnings: Narrower-Than-Expected Loss Despite Negative Stock ReactionEarnings Surprise Report - newsline.com
Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants - Stock Titan
Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59 - Stock Titan
Coherus Biosciences Announces 2026 Stockholder Meeting Results - The Globe and Mail
Coherus Oncology | 4: Statement of changes in beneficial ownership of securities-Officer McMichael Bryan J - Moomoo
Coherus Oncology, Inc. 8-K SEC Filing: Company Details, Stock Information, and Compliance Disclosures (May 27, 2026) - Minichart
Coherus Oncology shareholders approve director elections and equity plan changes - Investing.com Canada
Coherus Oncology shareholders approve director elections and equity plan changes By Investing.com - Investing.com South Africa
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):